Bococizumab: Difference between revisions
Sergekorjian (talk | contribs) (Created page with "__NOTOC__ File:Pharmacologic-interventions-for-PCSK9.jpg|250px|thumb|right|Pharmacologic interventions for PCSK9 <font size="1">''Adapted from Journal of the American Colle...") |
Sergekorjian (talk | contribs) |
||
| Line 5: | Line 5: | ||
{{CMG}} | {{CMG}} | ||
==Overview== | ==Overview== | ||
Bococizumab (PF-04950615; RN316) is a humanized monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 and is an investigational agent for the reduction of LDL-C levels in patients with hypercholesterolemia. | |||
==Properties== | ==Properties== | ||
Revision as of 20:42, 11 February 2015
For a review of all PCSK9 inhibitors please click here
|
WikiDoc Resources for Bococizumab |
|
Articles |
|---|
|
Most recent articles on Bococizumab Most cited articles on Bococizumab |
|
Media |
|
Powerpoint slides on Bococizumab |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Bococizumab at Clinical Trials.gov Clinical Trials on Bococizumab at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Bococizumab
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Bococizumab Discussion groups on Bococizumab Patient Handouts on Bococizumab Directions to Hospitals Treating Bococizumab Risk calculators and risk factors for Bococizumab
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Bococizumab |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Bococizumab (PF-04950615; RN316) is a humanized monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 and is an investigational agent for the reduction of LDL-C levels in patients with hypercholesterolemia.